No Data
No Data
Cooper Companies Raised to Buy at Jefferies on Valuation Disconnect
Johnson & Johnson Q2 Earnings Preview: Can New Drugs Lift Sagging Stock?
Johnson & Johnson (NYSE:JNJ) was one of the worst-performing Dow Jones Industrial Average stocks in the first half of 2024. Investors and analysts will be looking for the company to show progress from a mixed first quarter when second-quarter financial results are reported Wednesday, July 17.
Jefferies Maintains Alcon(ALC.US) With Buy Rating, Raises Target Price to $105
Jefferies analyst Michael Sarcone maintains $Alcon(ALC.US)$ with a buy rating, and adjusts the target price from $100 to $105.According to TipRanks data, the analyst has a success rate of 36.8% and
Jefferies Gives a Buy Rating to Alcon (ALC)
The Zacks Analyst Blog DexCom, Hologic, Alcon Intuitive Surgical and Thermo Fisher Scientific
Morgan Stanley Cuts STAAR to Underweight, Cites Growth Expectations
103480872 : congrats
sentosa island : Alco is good